Human urinary kallidinogenase in acute ischemic stroke: A single-arm, multicenter, phase IV study (RESK study).

Jun NiMing YaoLi-Hua WangMing YuRun-Hui LiLi-Hong ZhaoJia-Chun WangYin-Zhou WangXin WangHai-Qing SongBen-Yan LuoJia-Wei WangYi-Ning HuangLi-Ying Cuinull null

Published in: CNS neuroscience & therapeutics (2021)

HUK had an acceptable safety and tolerability profile in AIS patients. Besides, HUK demonstrated the neurological and functional improvements in AIS, further confirming its clinical efficacy in a real-world large population.

Keyphrases

end stage renal disease
endothelial cells
ejection fraction
chronic kidney disease
newly diagnosed
clinical trial
prognostic factors
peritoneal dialysis
cross sectional
patient reported outcomes
placebo controlled